| Symbol | MESO |
|---|
| Name | MESOBLAST LTD |
|---|
| Sector | HEALTH CARE |
|---|
| Region | Oceania |
|---|
| Industry | Biological Products, (No Diagnostic Substances) |
|---|
| Address | LEVEL 38, MELBOURNE, VICTORIA, C3 3000 |
|---|
| Telephone | 613 9639 6036 |
|---|
| Fax | — |
|---|
| Email | — |
|---|
| Website | https://www.mesoblast.com |
|---|
| Incorporation | UNDEFINED |
|---|
| Incorporated On | — |
|---|
| Employees | — |
|---|
| Fiscal Year | — |
|---|
| Public Since | — |
|---|
| Exchanges | NASDAQ |
|---|
| Auditor | — |
|---|
| Audit Status | NOT PROVIDED |
|---|
| Reporting Status | — |
|---|
| CIK | 0001345099 |
|---|
| Description | Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
Additional info from NASDAQ:
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. |
|---|
2026-06-30 23:56
Receives FDA BLA Filing Number and Requests Modular Review
Read more
2026-06-29 22:13
Becoming a substantial holder
Read more
2026-06-28 22:18
Ceasing to be a substantial holder
Read more
2026-06-24 23:55
Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
Read more
2026-06-15 22:18
Becoming a substantial holder
Read more
2026-06-11 22:23
Ceasing to be a substantial holder
Read more
2026-06-02 01:51
ASX CEO Connect Presentation
Read more
2026-04-29 23:56
Quarterly Activities/Appendix 4C Cash Flow Report
Read more
2026-04-29 07:09
New Form 3 - MESOBLAST LTD <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001213900-26-048797 <b>Size:</b> 5 KB
Read more
2026-04-28 23:50
Patient Recruitment Target Achieved in CLBP Pivotal Trial
Read more
No clinical trials found for this company.
No clinical products found for this company.